Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial - PubMed

3 months ago

Phase I trial testing a mutant KRAS vaccine with ipilimumab and nivolumab in resected pancreatic adenocarcinoma.
Vaccine targets six KRAS mutations (G12V, G12A, G12R, G12C, G12D, G13D).
Primary endpoints include safety and T cell response changes within 17 weeks.
Secondary endpoints include disease-free survival, overall survival, and long-term T cell responses.
Vaccine-related adverse events were grade 1-2.
11/12 patients showed increased T cell response to mutant KRAS antigens.
10/12 patients had tumor-specific responses.
Immunophenotyping revealed Th1 CD4 central memory and effector memory T cells.
Lower frequency of CD8 effector memory T cells observed.
Vaccine generated cross-reactive T cells recognizing multiple mutant KRAS antigens.
Findings support safety and diverse anti-tumor immunity of mutant KRAS vaccines.
Multiple authors report competing interests, including patents related to KRAS peptides/TCRs.

Hasty Briefsbeta